US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

269.70

+17.566.96%

Pre-market: 274.094.39+1.63%08:01 EDT

Volume:674.45K

Turnover:180.38M

Market Cap:31.95B

PE:-72.83

High:270.00

Open:269.30

Low:263.84

Close:252.14

Loading ...

Overview Company News Filings

RBC Raises Price Target on BeOne Medicines to $349 From $311, Keeps Outperform Rating

MT Newswires Live

RBC Capital Remains a Buy on BeOne Medicines (ONC)

Press Release: BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

BeOne Medicines Gets European Commission Approval for Nasopharyngeal Carcinoma Combination Treatment

MT Newswires Live

R&D Day Pipeline Updates Might Change The Case For Investing In BeOne Medicines (ONC)

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX)

BeOne Medicines Is Maintained at Overweight by Morgan Stanley

BeOne Medicines Price Target Maintained With a $311.00/Share by RBC Capital

BeOne Medicines' Brukinsa Tablets Recommended by European Medicine Committee

MT Newswires Live

BeOne Medicines Says Data Shows High Overall Response of Sonrotoclax plus BRUKINSA in CLL, MCL Patients

MT Newswires Live

BeOne says FDA approves table formulation of Brukinsa for approved indications

BeOne Medicines presents results from studies of BG-C9074, BG-68501 at ASCO

BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA

BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland

MT Newswires Live

Sector Update: Health Care

MT Newswires Live

BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use

BeiGene receives positive CHMP opinion for Tevimbra

Beigene's Cancer Drug Tevimbra Recommended by EU Panel for Extension of Indication

MT Newswires Live

Stock Track | BeiGene Plummets 5.60% in Pre-market as Trump's Drug Pricing Plan Rattles Pharma Stocks

Stock Track | BeiGene Plunges 6.86% as Trump's Drug Price Plan Rattles Asia Pharma Stocks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ONC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":269.7,"timestamp":1752609600000,"preClose":252.14,"halted":0,"volume":674447,"hourTrading":{"tag":"盘前","latestPrice":274.09,"preClose":269.7,"latestTime":"08:01 EDT","volume":443,"amount":120773.07878,"timestamp":1752667282115},"delay":0,"floatShares":75541600,"shares":118450658,"eps":-3.70325,"marketStatus":"Pre-Mkt","change":17.56,"latestTime":"07-16 08:24:37 EDT","open":269.3,"high":270,"low":263.84,"amount":180381619.01958,"amplitude":0.024431,"askPrice":274.09,"askSize":10,"bidPrice":270.5,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1752672600000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":269.7,"preHourTrading":{"tag":"盘前","latestPrice":274.09,"preClose":269.7,"latestTime":"08:01 EDT","volume":443,"amount":120773.07878,"timestamp":1752667282115},"postHourTrading":{"tag":"盘后","latestPrice":269.7,"preClose":269.7,"latestTime":"19:16 EDT","volume":5670,"amount":1529173.84,"timestamp":1752621382274},"volumeRatio":2.571979128390765,"impliedVol":0.4729,"impliedVolPercentile":0.803},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":2.571979128390765,"shares":118450658,"dividePrice":0,"high":270,"amplitude":0.024431,"preClose":252.14,"low":263.84,"week52Low":146.87,"pbRate":"9.13","psRate":"7.65","week52High":287.88,"institutionHeld":0,"latestPrice":269.7,"committee":-0.333333,"eps":-3.70325,"divideRate":0,"volume":674447,"delay":0,"ttmEps":-3.70325,"open":269.3,"prevYearClose":184.71,"prevWeekClose":250.3,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":244.47,"twentyDayClose":269.63,"sixtyDayClose":228.14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551408081","title":"RBC Raises Price Target on BeOne Medicines to $349 From $311, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2551408081","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551408081?lang=en_us&edition=fundamental","pubTime":"2025-07-16 19:35","pubTimestamp":1752665737,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) has an average rating of buy and mean price target of $337.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","ONC"],"gpt_icon":0},{"id":"2551147807","title":"RBC Capital Remains a Buy on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2551147807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551147807?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:51","pubTimestamp":1752663111,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines today and set a price target of $349.00. The company’s shares closed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-beone-medicines-onc-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","MDCO","BK4139","LU0310800379.SGD","LU1267930573.SGD","LU0029864427.USD","LU0708994859.HKD","ONC","BK4207","LU0128525929.USD"],"gpt_icon":0},{"id":"2551144997","title":"Press Release: BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2551144997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551144997?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:04","pubTimestamp":1752660240,"startTime":"0","endTime":"0","summary":"BeOne Medicines Ltd. , a global oncology company, will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled \"Risk Factors\" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission  as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All inf","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4139","MDCO","ONC"],"gpt_icon":0},{"id":"2550644408","title":"BeOne Medicines Gets European Commission Approval for Nasopharyngeal Carcinoma Combination Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2550644408","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550644408?lang=en_us&edition=fundamental","pubTime":"2025-07-10 19:08","pubTimestamp":1752145731,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Thursday the European Commission approved Tevimbra in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma not amenable to curative surgery or radiotherapy.The company said the indication is based on results of a study that showed a \"statistically significant\" improvement in progression-free survival.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","MDCO","BK4526","BK4139"],"gpt_icon":0},{"id":"2550645359","title":"R&D Day Pipeline Updates Might Change The Case For Investing In BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550645359","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550645359?lang=en_us&edition=fundamental","pubTime":"2025-07-10 14:12","pubTimestamp":1752127949,"startTime":"0","endTime":"0","summary":"• BeOne Medicines recently unveiled major advancements to its oncology pipeline during an investor R&D Day, showcasing more than 40 assets in clinical and commercial stages and presenting new clinical data for B-cell and solid tumor programs.\n\n• An important highlight was compelling early data on the combination of sonrotoclax and BRUKINSA in CLL, which could influence future standards of care in hematologic cancers.\n\n• We'll explore how this potential for a new fixed-duration CLL treatment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/rd-day-pipeline-updates-might-change-the-case-for-investing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONC","MDCO","BK4139","BK4526"],"gpt_icon":0},{"id":"2548386069","title":"Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548386069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548386069?lang=en_us&edition=fundamental","pubTime":"2025-07-02 17:10","pubTimestamp":1751447412,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (ONC – Research Report), Apellis Pharmaceuticals (APLS – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beigene-onc-apellis-pharmaceuticals-apls-and-pliant-therapeutics-plrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beigene-onc-apellis-pharmaceuticals-apls-and-pliant-therapeutics-plrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HCSG","BK4526","BK4139","BK4007","BK4585","BK4505","PLRX","APLS","LU1093756325.SGD","BK4137","ONC","LU1093756168.USD"],"gpt_icon":0},{"id":"2546740033","title":"BeOne Medicines Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2546740033","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546740033?lang=en_us&edition=fundamental","pubTime":"2025-06-28 00:04","pubTimestamp":1751040240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 27, 2025 12:04 ET (16:04 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2546749341","title":"BeOne Medicines Price Target Maintained With a $311.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2546749341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546749341?lang=en_us&edition=fundamental","pubTime":"2025-06-27 21:07","pubTimestamp":1751029620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 27, 2025 09:07 ET (13:07 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2546219275","title":"BeOne Medicines' Brukinsa Tablets Recommended by European Medicine Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2546219275","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546219275?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:32","pubTimestamp":1750847550,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Wednesday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a new film-coated tablet formulation of its Brukinsa B-cell cancer drug for all approved indications.The opinion is subject to a review by the European Commission, which will grant the marketing authorization for the tablet formulation in the region.The company said it will start converting Brukinsa to tablets from capsules in regions outside China in 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","MDCO","BK4139","BK4526"],"gpt_icon":0},{"id":"2542515460","title":"BeOne Medicines Says Data Shows High Overall Response of Sonrotoclax plus BRUKINSA in CLL, MCL Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2542515460","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542515460?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:10","pubTimestamp":1749726616,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) said Thursday that the phase 1 study of sonrotoclax plus BRUKINSA elicited a 96% overall response rate in relapsed/refractory chronic lymphocytic leukemia patients and a 79% over","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONC","MDCO","BK4139","BK4526"],"gpt_icon":0},{"id":"2542953750","title":"BeOne says FDA approves table formulation of Brukinsa for approved indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2542953750","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542953750?lang=en_us&edition=fundamental","pubTime":"2025-06-12 04:10","pubTimestamp":1749672624,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. Food and Drug Administration has approved a new tablet formulation of BRUKINSA for all five approved ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-says-fda-approves-table-formulation-of-brukinsa-for-approved-indications-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-says-fda-approves-table-formulation-of-brukinsa-for-approved-indications-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4139","BK4526"],"gpt_icon":0},{"id":"2540676444","title":"BeOne Medicines presents results from studies of BG-C9074, BG-68501 at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2540676444","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540676444?lang=en_us&edition=fundamental","pubTime":"2025-06-02 18:15","pubTimestamp":1748859321,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology Annual Meet...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-presents-results-from-studies-of-bg-c9074-bg-68501-at-asco-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-presents-results-from-studies-of-bg-c9074-bg-68501-at-asco-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BG","LU0251142724.SGD","LU2211817866.USD","LU0471298694.HKD","ONC","LU0251131958.USD","LU0742534661.SGD","BK4139","LU0048573561.USD","BK4588","LU2360106947.USD","MDCO","BK4526","LU0385154629.USD","BK4189","LU0471298777.SGD","BK4585"],"gpt_icon":0},{"id":"2540308077","title":"BeOne Medicines to present new data from Phase 3 SEQUOIA trial of BRUKINSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2540308077","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540308077?lang=en_us&edition=fundamental","pubTime":"2025-06-02 03:50","pubTimestamp":1748807415,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA. These data will ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-to-present-new-data-from-phase-3-sequoia-trial-of-brukinsa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-to-present-new-data-from-phase-3-sequoia-trial-of-brukinsa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4141","BK4588","BK4543","MDCO","LU0348723411.USD","BK4139","IE00BMPRXN33.USD","IE00BMPRXQ63.HKD","BK4585","BK4609","IE00BMPRXR70.SGD","BK4526"],"gpt_icon":0},{"id":"2538464563","title":"BeiGene Changes Name to BeOne Medicines, Completes Redomiciliation to Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2538464563","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538464563?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:34","pubTimestamp":1748352847,"startTime":"0","endTime":"0","summary":"BeiGene  said Tuesday it has changed its name to BeOne Medicines and completed its redomiciliation to Switzerland.The company said its shareholders approved the new name and redomiciliation to Switzerland from the Cayman Islands on April 28.The transition to its new name throughout its global operations will take effect in phases, the company added.BeOne's shares were up more than 1% in early trading Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","06160","MDCO","ONC","BK4526"],"gpt_icon":0},{"id":"2538646180","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2538646180","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538646180?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:01","pubTimestamp":1748350877,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Tuesday as the Health Care Select Sector SPDR Fund  was up 0.9% and the iShares Biotechnology ETF  rose by 1.1% recently.BeiGene  shares were slightly down after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of its drug Tevimbra in combination with gemcitabine and cisplatin as a first-line treatment for adults with recurrent or metastatic nasopharyngeal cancer.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","BK4588","BK4585","IBB","BK4581","BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2538468004","title":"BeiGene's Tevimbra Gets Positive Opinion from Committee for Medicinal Products for Human Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468004","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468004?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:12","pubTimestamp":1748344320,"startTime":"0","endTime":"0","summary":"BeiGene's Tevimbra gets a highly sought after recommendation.The oncology company said the European Medicines Agency's Committee for Medicinal Products for Human Use  issued a positive opinion of its treatment in combination with gemcitabine and cisplatin for adults with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal cancer.Nasopharyngeal cancer is a type of head and neck cancer that starts in the upper throat passage that connects the nose to the lungs.Mark Lanasa, chief medical officer, solid tumors at BeiGene, said the announcement marks a second positive CHMP opinion for Tevimbra this year.Tevimbra is currently approved in the European Union as a first-line treatment for eligible patients with gastric or gastroesophageal junction adenocarcinoma, among other use cases.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","CHMP","BK1588","LU2328871848.SGD","06160","ONC","BK1500","BK4087","BK4139","BK1161","BK4526","LU0588546209.SGD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2538445086","title":"BeiGene receives positive CHMP opinion for Tevimbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2538445086","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538445086?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:10","pubTimestamp":1748340648,"startTime":"0","endTime":"0","summary":"BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinion-for-tevimbra-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinion-for-tevimbra-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4526","ONC","BK4087","CHMP"],"gpt_icon":0},{"id":"2537371571","title":"Beigene's Cancer Drug Tevimbra Recommended by EU Panel for Extension of Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2537371571","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537371571?lang=en_us&edition=fundamental","pubTime":"2025-05-23 22:13","pubTimestamp":1748009639,"startTime":"0","endTime":"0","summary":"The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it recommended an extension of therapeutic indication for Beigene's  cancer drug Tevimbra.Tevimbra is already authorized in the EU, the committee said, with indications for non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, and oesophageal squamous cell carcinoma.Price: 240.05, Change: +1.29, Percent Change: +0.54","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","BK4139","ONC","BK4156","06160"],"gpt_icon":0},{"id":"1162268752","title":"Stock Track | BeiGene Plummets 5.60% in Pre-market as Trump's Drug Pricing Plan Rattles Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1162268752","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162268752?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:04","pubTimestamp":1747051447,"startTime":"0","endTime":"0","summary":"BeiGene Ltd.  shares plunged 5.60% in pre-market trading on Monday, following President Trump's announcement of an executive order aimed at lowering prescription drug costs in the United States. The move has sent shockwaves through the Asian pharmaceutical sector, with BeiGene among the hardest hit.The sharp decline comes after President Trump declared his intention to sign an executive order implementing a \"Most Favored Nation\" policy. This policy would tie U.S. government drug prices to those ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"1190598443","title":"Stock Track | BeiGene Plunges 6.86% as Trump's Drug Price Plan Rattles Asia Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1190598443","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190598443?lang=en_us&edition=fundamental","pubTime":"2025-05-12 10:04","pubTimestamp":1747015462,"startTime":"0","endTime":"0","summary":"BeiGene Ltd.  experienced a significant 24-hour plunge of 6.86% in the night session, as President Trump's announcement to lower prescription drug costs sent shockwaves through the Asian pharmaceutical sector.The decline comes in response to President Trump's declaration that he would sign an executive order implementing a \"Most Favored Nation\" policy. This policy aims to tie U.S. government drug prices to those paid by other countries, potentially affecting the profitability of pharmaceutical c","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | BeiGene Plunges 6.86% as Trump's Drug Price Plan Rattles Asia Pharma Stocks","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":94,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"Pre-Market","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-15","current":-76.118086,"percent":0.060284,"low":-89.808695,"twenty":-46.059796,"median":-39.216526,"eighty":-23.173462,"high":-19.234246,"avg":-39.781569,"sd":17.935645,"marketCap":29866148908},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-15","current":-76.118086,"twenty":-46.059796,"median":-39.216526,"eighty":-23.173462,"marketCap":29866148908}],"updateTime":1752668677866}}}